Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Summary of the main characteristics of the six subtypes. Symbols correspond to the relative frequency within the subtype (o: very low frequencies [∼0%]; +++: very high frequencies; +/++: intermediate frequencies), and arrows indicate significant enrichment of subtype up- and down-regulated genes in most of the pathways of the given category. EMT, epithelial–mesenchymal transition; SC, stem cell; Wnt pw, Wnt pathway.](https://figures.cochat.ai/paper-figures/d9e6ea3312ee4d83b17b55c403c90fdb/gene-expression-classification-of-colon-cancer-into-molecular-subtypes-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, the MEKi bypass resistance was strongly correlated with the SRC activation/dasatinib sensitivity, the EMT-like stemness and the CMS4 subtype (see Fig. 6 and Fig. 7 as well as Additional File 3_Fig S5 and Fig S6).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar results were seen in Marisa 458 CMS1-4 CRC tumors (Fig. 8d).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“To obtain a robust classification, we used a consensus unsupervised approach [22] implemented in the R package ConsensusClusterPlus.”
MethodWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Research works printed but not linked: 1
- American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.
Cited by
Items 301–400 of 1,001
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 51
Lee, J., Jung, S., Park, W. S., Choe, E. K., Kim, E., Shin, R., Heo, S. C., Lee, J. H., Kim, K., & Chai, Y. J. (2019) · Scientific Reports · doi:10.1038/s41598-018-38116-y · Cited by 50
The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer
Subtil, B., Cambi, A., Tauriello, D. V. F., & de Vries, I. J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724883 · Cited by 50
Okrah, K., Tarighat, S., Liu, B., Koeppen, H., Wagle, M. C., Cheng, G., Sun, C., Dey, A., Chang, M. T., Sumiyoshi, T., et al. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0068-8 · Cited by 49
Xiong, Y., Wang, R., Peng, L., You, W., Wei, J., Zhang, S., Wu, X., Guo, J., Xu, J., Lv, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20013 · Cited by 49
Dugo, M., Nicolini, G., Tragni, G., Bersani, I., Tomassetti, A., Colonna, V., Vecchio, M. D., de Braud, F., Canevari, S., Anichini, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3007 · Cited by 50
Le Corre, D., Ghazi, A., Balogoun, R., Pilati, C., Aparicio, T., Martin-Lannerée, S., Marisa, L., Djouadi, F., Poindessous, V., Crozet, C., et al. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.07.036 · Cited by 48
Self-citationCombination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer
Zhang, X., Quan, F., Xu, J., Xiao, Y., Li, X., & Li, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108412 · Cited by 48
Ragulan, C., Eason, K., Fontana, E., Nyamundanda, G., Tarazona, N., Patil, Y., Poudel, P., Lawlor, R. T., Del Rio, M., Koo, S.-L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43492-0 · Cited by 48
Downregulated SPINK4 is associated with poor survival in colorectal cancer
Wang, X., Yu, Q., Ghareeb, W. M., Zhang, Y., Lu, X., Huang, Y., Huang, S., Sun, Y., Lin, J., Liu, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6484-5 · Cited by 48
Di, Z., Di, M., Fu, W., Tang, Q., Liu, Y., Lei, P., Gu, X., Liu, T., & Sun, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00192 · Cited by 48
Re, V. D., Caggiari, L., Zorzi, M. D., Talamini, R., Racanelli, V., Andrea, M. D., Buonadonna, A., Zagonel, V., Cecchin, E., Innocenti, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084940 · Cited by 48
Li, C., Singh, B., Graves-Deal, R., Ma, H., Starchenko, A., Fry, W. H., Lu, Y., Wang, Y., Bogatcheva, G., Khan, M. P., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618297114 · Cited by 47
The panoramic picture of pepsinogen gene family with pan‐cancer
Shen, S., Li, H., Liu, J., Sun, L. L., & Yuan, Y. (2020) · Cancer Medicine · doi:10.1002/cam4.3489 · Cited by 47
Yang, S., Wang, Z., Wang, C., Li, C., & Wang, B. (2024) · Journal of Cancer · doi:10.7150/jca.93215 · Cited by 47
den Uil, S. H., Coupé, V. M. H., Linnekamp, J. F., van den Broek, E., Goos, J. A. C. M., Diemen, P. M. D., Belt, E. J. T., van Grieken, N. C. T., Scott, P. M., Vermeulen, L., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.376 · Cited by 47
Lopez, D., Montoya, D. J., Ambrose, M., Lam, L., Briscoe, L., Adams, C., Modlin, R. L., & Pellegrini, M. A. (2017) · BMC Genomics · doi:10.1186/s12864-017-4167-7 · Cited by 47
van der Waals, L. M., Rinkes, I. H. M. B., & Kranenburg, O. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205536 · Cited by 47
Neoadjuvant chemotherapy affects molecular classification of colorectal tumors
Trumpi, K., Ubink, I., Trinh, A., Djafarihamedani, M., Jongen, J. M., Govaert, K. M., Elias, S. G., van Hooff, S. R., Medema, J. P., Lacle, M. M., et al. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.48 · Cited by 46
SIX4 promotes metastasis via activation of the PI3K-AKT pathway in colorectal cancer
Li, G., Hu, F., Luo, X., Hu, J., & Feng, Y. (2017) · PeerJ · doi:10.7717/peerj.3394 · Cited by 46
Bibeau, F., Dorbeau, M., & Bazille, C. (2017) · Côlon & Rectum · doi:10.1007/s11725-017-0730-2 · Cited by 46
Upregulation of STC2 in colorectal cancer and its clinicopathological significance
Zhang, C., Chen, S., Ma, X., Yang, Q., Su, F., Shu, X., Xie, W., Feng, M., & Xiong, B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s191609 · Cited by 46
Pelullo, M., Nardozza, F., Zema, S., Quaranta, R., Nicoletti, C., Besharat, Z. M., Felli, M. P., Cerbelli, B., d’Amati, G., Palermo, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0145 · Cited by 46
Co-clustering Ensembles based on Multiple Relevance Measures
Yu, X., Yu, G., Wang, J., & Domeniconi, C. (2019) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2019.2942029 · Cited by 46
Human Colorectal Cancer from the Perspective of Mouse Models
Šťastná, M., Janečková, L., Hrčkulák, D., Kříž, V., & Kořínek, V. (2019) · Genes · doi:10.3390/genes10100788 · Cited by 47
Hemming, M. L., Fan, C., Raut, C. P., Demetri, G. D., Armstrong, S. A., Sicińska, E., & George, S. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0197 · Cited by 46
GABRD promotes progression and predicts poor prognosis in colorectal cancer
Niu, G., Deng, L., Zhang, X., Hu, Z., Han, S., Xu, K., Hong, R., Meng, H., & Ke, C. (2020) · Open Medicine · doi:10.1515/med-2020-0128 · Cited by 46
Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors
Wang, L., Londono, L. M., Cowell, J., Saatci, Ö., Aras, M., Ersan, P. G., Serra, S., Pei, H., Clift, R., Zhao, Q., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0340 · Cited by 46
Kim, J. H., Seo, M.-K., Lee, J. A., Yoo, S., Oh, H. J., Kang, H., Cho, N., Bae, J. M., Kang, G. H., & Kim, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003414 · Cited by 46
Jennings, B. A., & Willis, G. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.024 · Cited by 46
GECC: Gene Expression Based Ensemble Classification of Colon Samples
Rathore, S., Hussain, M., & Khan, A. (2014) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2014.2344655 · Cited by 46
Inoue, A., Deem, A. K., Kopetz, S., Heffernan, T. P., Draetta, G. F., & Carugo, A. (2019) · Cancers · doi:10.3390/cancers11091321 · Cited by 45
Liver X receptor unlinks intestinal regeneration and tumorigenesis
Das, S., Parigi, S. M., Luo, X., Fransson, J., Kern, B. C., Okhovat, M. A., Diaz, O. E., Sorini, C., Czarnewski, P., Webb, A., et al. (2024) · Nature · doi:10.1038/s41586-024-08247-6 · Cited by 45
Loss of colonic fidelity enables multilineage plasticity and metastasis
Cammareri, P., Raponi, M., Hong, Y., Billard, C. V., Peckett, N., Zhu, Y., Velez-Bravo, F. D., Younger, N. T., Dunican, D. S., Pohl, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09125-5 · Cited by 45
Strategies to Prevent “Bad Luck” in Cancer
Albini, A., Cavuto, S., Apolone, G., & Noonan, D. M. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv213 · Cited by 45
The potential role of platelets in the consensus molecular subtypes of colorectal cancer
Lam, M. S., Roszik, J., Marie, P. K., Davis, J. S., Morris, J. S., Kopetz, S., & Menter, D. G. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9678-9 · Cited by 45
Árnadóttir, S. S., Jeppesen, M., Lamy, P., Bramsen, J. B., Nordentoft, I., Knudsen, M., Vang, S., Madsen, M. R., Thastrup, M., Thastrup, J., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12156 · Cited by 47
Ullmann, P., Rodriguez, F., Schmitz, M., Meurer, S. K., Qureshi-Baig, K., Felten, P., Ginolhac, A., Antunes, L., Frasquilho, S., Zügel, N., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3003 · Cited by 45
Prognostic role of FUT8 expression in relation to p53 status in stage II and III colorectal cancer
Noda, M., Okayama, H., Kofunato, Y., Chida, S., Saito, K., Tada, T., Ashizawa, M., Nakajima, T., Aoto, K., Kikuchi, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200315 · Cited by 45
Clinical Proteomics in Colorectal Cancer, a Promising Tool for Improving Personalised Medicine
Chauvin, A., & Boisvert, F. (2018) · Proteomes · doi:10.3390/proteomes6040049 · Cited by 47
RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy
Zheng, W., Rañoa, D. R. E., Huang, X., Hou, Y., Yang, K., Poli, E. C., Beckett, M. A., Fu, Y., & Weichselbaum, R. R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2324 · Cited by 45
HGF/c-Met Signalling in the Tumor Microenvironment
Zambelli, A., Biamonti, G., & Amato, A. M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_2 · Cited by 46
Qian, Z., Zhang, G., Song, G., Shi, J., Gong, L., Mou, Y., & Han, Y. K. (2017) · Oncotarget · doi:10.18632/oncotarget.16064 · Cited by 44
Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene
Clark, C. R., Maile, M., Blaney, P., Hellweg, S. R., Strauss, A., Durose, W. W., Priya, S., Habicht, J. L., Burns, M. B., Blekhman, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33527-3 · Cited by 44
Zhang, Z., Huang, L., Li, J., & Wang, P. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04657-3 · Cited by 44
Rönsch, K., Jägle, S., Rose, K., Seidl, M., Baumgartner, F., Freihen, V., Yousaf, A., Metzger, E., Laßmann, S., Schüle, R., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.016 · Cited by 44
αSMA+ fibroblasts suppress Lgr5+ cancer stem cells and restrain colorectal cancer progression
McAndrews, K. M., Vázquez-Arreguín, K., Kwak, C., Sugimoto, H., Zheng, X., Li, B., Kirtley, M. L., LeBleu, V. S., & Kalluri, R. (2021) · Oncogene · doi:10.1038/s41388-021-01866-7 · Cited by 43
Kwon, Y., Park, M., Jang, M., Yun, S., Kim, W. K., Kim, S., Paik, S., Lee, H. J., Hong, S., Kim, T. I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17023 · Cited by 43
Liu, X., Zhang, S., An, Y., Xu, B., Yan, G., & Sun, M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03357-z · Cited by 43
Clinical Application of Genetics in Management of Colorectal Cancer
Kim, E. R., & Kim, Y.-H. (2014) · Intestinal Research · doi:10.5217/ir.2014.12.3.184 · Cited by 43
Martínez‐Ciarpaglini, C., Oltra, S. S., Roselló, S., Roda, D., Mongort, C., Carrasco, F., González, J., Gómez, F. J. S., Tarazona, N., Huerta, M., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0124-5 · Cited by 43
Pathway-based subnetworks enable cross-disease biomarker discovery
Haider, S., Yao, C. Q., Sabine, V. S., Grzadkowski, M. R., Stimper, V., Starmans, M. H. W., Wang, J., Nguyen, F., Moon, N. C., Lin, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07021-3 · Cited by 43
Kok, C. H., Yeung, D. T. O., Liu, L., Watkins, D. B., Leclercq, T. M., Dang, P., Saunders, V. A., Reynolds, J., White, D. L., & Hughes, T. P. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000195 · Cited by 43
DUSP10 regulates intestinal epithelial cell growth and colorectal tumorigenesis
Png, C. W., Weerasooriya, M., Guo, J., James, S. J., Poh, H.-M., Osato, M., Flavell, R. A., Dong, C., Yang, H. H., & Zhang, Y. (2015) · Oncogene · doi:10.1038/onc.2015.74 · Cited by 45
Schell, M. J., Yang, M., Missiaglia, E., Delorenzi, M., Soneson, C., Yue, B., Nebozhyn, M. V., Loboda, A., Bloom, G., & Yeatman, T. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0143 · Cited by 42
Michael, I. P., Saghafinia, S., Tichet, M., Zangger, N., Marinoni, I., Perren, A., & Hanahan, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.015 · Cited by 42
Canlı, S. D., Gömceli, İ., İşbilen, M., Dayanç, B. E., Tez, M., Bostancı, E. B., Turhan, N., Akoğlu, M., Ozyerli‐Goknar, E., Durdu, S., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17872 · Cited by 42
Levolger, S., van Vledder, M. G., Alberda, W. J., Verhoef, C., de Bruin, R. W. F., IJzermans, J. N. M., & Burger, J. W. A. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.028 · Cited by 42
Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence
Letellier, E., Schmitz, M., Ginolhac, A., Rodriguez, F., Ullmann, P., Qureshi-Baig, K., Frasquilho, S., Antunes, L., & Haan, S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.352 · Cited by 42
Establishment of a 12-gene expression signature to predict colon cancer prognosis
Sun, D., Chen, J., Liu, L., Zhao, G., Dong, P., Wu, B., Wang, J., & Dong, L. (2018) · PeerJ · doi:10.7717/peerj.4942 · Cited by 42
Combining DNA methylation and RNA sequencing data of cancer for supervised knowledge extraction
Cappelli, E., Felici, G., & Weitschek, E. (2018) · BioData Mining · doi:10.1186/s13040-018-0184-6 · Cited by 42
Bonamy, C., Séchet, E., Amiot, A., Alam, A., Mourez, M., Fraisse, L., Sansonetti, P. J., & Sperandio, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-36387-z · Cited by 42
The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer
McCuaig, S., Barras, D., Mann, E. H., Friedrich, M., Bullers, S. J., Janney, A., Garner, L. C., Domingo, E., Koelzer, V. H., Delorenzi, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1086 · Cited by 42
Wang, K., Huang, C., & Nice, E. C. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.894466 · Cited by 42
Koi, M., Garcia, M., Choi, C., Kim, H.-R., Koike, J., Hemmi, H., Nagasaka, T., Okugawa, Y., Toiyama, Y., Kitajima, T., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.032 · Cited by 42
Zhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Luo, W., Dai, W., Li, Q., Mo, S., Han, L., Xiao, X., Gu, R., Xiang, W., Ye, L., Wang, R., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69808 · Cited by 41
Galatenko, V., Galatenko, A. V., Samatov, T. R., Turchinovich, A. A., Shkurnikov, M. Y., Makarova, J. A., & Tonevitsky, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-20215-5 · Cited by 41
Spinner, C. A., Lamsoul, I., Métais, A., Fébrissy, C., Moog‐Lutz, C., & Lutz, P. G. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0562 · Cited by 41
A SMAD4 ‐modulated gene profile predicts disease‐free survival in stage II and III colorectal cancer
Szeglin, B. C., Wu, C., Marco, M. R., Park, H. S., Zhang, Z., Zhang, B., García‐Aguilar, J., Beauchamp, R. D., Chen, X. S., & Smith, J. J. (2021) · Cancer Reports · doi:10.1002/cnr2.1423 · Cited by 41
Ma, H., Qiu, Q., Tan, D., Chen, Q., Liu, Y., Chen, B., & Wang, M. (2022) · Biomolecules · doi:10.3390/biom13010062 · Cited by 41
Meng, H., Nan, M., Li, Y., Ding, Y., Yin, Y., & Zhang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148412 · Cited by 42
Ko, J., Gu, W., Lim, I., Zhou, T., & Bang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110094 · Cited by 41
GADD45β Loss Ablates Innate Immunosuppression in Cancer
Verzella, D., Bennett, J., Fischietti, M., Thotakura, A. K., Recordati, C., Pasqualini, F., Capece, D., Vecchiotti, D., D’Andrea, D., Francesco, B. D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1833 · Cited by 41
Ubink, I., Elias, S. G., Moelans, C. B., Laclé, M. M., van Grevenstein, W. M. U., van Diest, P. J., Borel Rinkes, I. H. M., & Kranenburg, O. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw303 · Cited by 40
YAP/TAZ signalling in colorectal cancer: lessons from consensus molecular subtypes
Mouillet-Richard, S., & Laurent-Puig, P. (2020) · Cancers · doi:10.3390/cancers12113160 · Cited by 40
Self-citationNapolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1497-0 · Cited by 40
Endo, E., Okayama, H., Saito, K., Nakajima, S., Yamada, L., Ujiie, D., Kase, K., Fujita, S., Endo, H., Sakamoto, W., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0308 · Cited by 40
Identification of key tumorigenesis‑related genes and their microRNAs in colon cancer
Xie, B., Zhao, R., Bai, B., Wu, Y., Xu, Y., Si, L., Fang, Y., Wang, Z., Maswikiti, E. P., Zhou, X., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6726 · Cited by 40
Prognostic implications of metabolism-associated gene signatures in colorectal cancer
Miao, Y., Li, Q., Wang, J., Quan, W., Li, C., Yang, Y., & Mi, D. (2020) · PeerJ · doi:10.7717/peerj.9847 · Cited by 40
Mo, X., Huang, X., Feng, Y., Wei, C., Liu, H., Ru, H., Qin, H., Lai, H., Wu, G., Xie, W., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1832347 · Cited by 40
Chr20q Amplification Defines a Distinct Molecular Subtype of Microsatellite Stable Colorectal Cancer
Zhang, B., Yao, K., Zhou, E., Zhang, L., & Cheng, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4009 · Cited by 40
Integrin β7 Inhibits Colorectal Cancer Pathogenesis via Maintaining Antitumor Immunity
Zhang, Y., Xie, R., Zhang, H., Zheng, Y., Lin, C., Yang, L., Huang, M., Li, M., Song, F., Lu, L., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0879 · Cited by 40
Mohammed, M., Mboya, I. B., Mwambi, H. G., Elbashir, M. K., & Omolo, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261625 · Cited by 40
Colorectal cancer carcinogenesis: From bench to bedside
Currais, P., Rosa, I., & Claro, I. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i3.654 · Cited by 40
Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer
Liu, Z., Weng, S., Dang, Q., Xu, H., Ren, Y., Guo, C., Xing, Z., Sun, Z., & Han, X. (2022) · eLife · doi:10.7554/elife.81114 · Cited by 40
What We Know About Stage II and III Colon Cancer: It’s Still Not Enough
Puccini, A., Berger, M. D., Zhang, W., & Lenz, H. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0494-5 · Cited by 40
Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer
Torrens‐Mas, M., Hernández‐López, R., Oliver, J., Roca, P., & Sastre‐Serra, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26443 · Cited by 40
Cheng, J., Guo, Y., Gao, Q., Li, H., Yan, H., Li, M., Cai, H., Zheng, W., Li, X., Jiang, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15754 · Cited by 39
Eide, P. W., Eilertsen, I. A., Sveen, A., & Lothe, R. A. (2019) · International Journal of Cancer · doi:10.1002/ijc.31998 · Cited by 39
Loevenich, L. P., Tschurtschenthaler, M., Rokavec, M., Silva, M. G., Jesinghaus, M., Kirchner, T., Klauschen, F., Saur, D., Neumann, J. H. L., Hermeking, H., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1247 · Cited by 40
Fátrai, S., van Schelven, S. J., Ubink, I., Govaert, K. M., Raats, D., Köster, J., Verheem, A., Rinkes, I. H. M. B., & Kranenburg, O. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.003 · Cited by 39
Dienstmann, R., Salazar, R., & Tabernero, J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.91 · Cited by 38
Liu, D., Shen, X., Zhu, G., & Xing, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5391 · Cited by 38
Picardo, F., Romanelli, A., Muinelo‐Romay, L., Mazza, T., Fusilli, C., Parrella, P., Barbazán, J., López‐López, R., Barbano, R., Robertis, M. D., et al. (2019) · Cancers · doi:10.3390/cancers11101598 · Cited by 40
Tieng, F. Y. F., Abu, N., Lee, L., & Mutalib, N. A. (2021) · Diagnostics · doi:10.3390/diagnostics11030544 · Cited by 38
The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer
Carberry, S., D’Orsi, B., Monsefi, N., Salvucci, M., Bacon, O., Fay, J., Rehm, M., McNamara, D. A., Kay, E. W., & Prehn, J. H. M. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0140-2 · Cited by 38
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
Advani, S., Advani, P. S., Brown, D. W., DeSantis, S. M., Korphaisarn, K., VonVille, H. M., Bressler, J., López, D. S., Davis, J. S., Daniel, C. R., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6144-9 · Cited by 38
Chen, C., Aihemaiti, M., Zhang, X., Qu, H., Sun, Q.-L., He, Q., & Yu, W. (2018) · Europe PMC (PubMed Central) · Cited by 38
Carrillo-Perez, F., Pizurica, M., Zheng, Y., Nandi, T. N., Madduri, R., Shen, J., & Gevaert, O. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01193-8 · Cited by 37
“…or expression of a single protein) or the classification of tumours into a limited number of discrete classes (such as consensus molecular subtypes 50 ), few attempts have been made to explore how changes in the expression of thousands of genes might be reflected in routine H&E tumour…”
Metadata
- Authors
- Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., Parc, Y., Olschwang, S., Milano, G., Laurent-Puig, P., & Boige, V.
- Affiliations
- Inserm (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- La Ligue Contre le Cancer (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hôpital Européen Georges-Pompidou (FR)
- CHU Dijon Bourgogne (FR)
- Institut Gustave Roussy (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e1001453
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3660251
- OpenAlex
- W2154941270
- Cited by
- 1,507
- References
- 40
- Citations by year
- 2026: 84 · 2025: 111 · 2024: 108 · 2023: 142 · 2022: 145 · 2021: 194 · 2020: 131 · 2019: 126 · 2018: 131 · 2017: 108 · 2016: 90 · 2015: 74 · 2014: 53 · 2013: 8
- FWCI
- 56.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- colon cancer, molecular subtypes, gene expression signatures, mismatch repair deficiency, chromosomal instability, KRAS mutation, BRAF mutation, TP53 mutation, CpG island methylator phenotype, Wnt signaling, relapse-free survival, prognosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms, Female, France, Genetic Testing, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, RNA, Messenger, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Cluster Analysis, Chi-Square Distribution, Logistic Models, Proportional Hazards Models, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.